Amylin
Human Islet Amyloid Polypeptide (Amylin, IAPP)
37 aa Amino Acids · MW: 3900 Da
Amino Acids
37 aa
Molecular Weight
3900 Da
Half-life
10-20 minutes
Research Score
4.3
Studies
520
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Amylin?
Amylin is a pancreatic beta-cell peptide that slows gastric emptying and promotes fullness after meals. It is a well-studied satiety signal and a close biologic counterpart to pramlintide, but this entry refers to the native peptide.
Key Benefits & Mechanisms
slower gastric emptying
increased post-meal satiety
reduced meal size
blunted postprandial glucose rise
Research Summary
Amylin has been studied for appetite reduction, gastric-emptying delay, and synergy with other satiety pathways. The literature supports a mechanistic role in short-term satiety and meal termination.
Related Peptides
Oxyntomodulin
Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide
Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.
Weight ManagementCotadutide
MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist
Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.
Weight ManagementMazdutide
IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist
Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.
Weight ManagementDulaglutide
Recombinant GLP-1 receptor agonist Fc fusion protein
Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.
Weight Management